Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung

Clinical Cancer Research

Volumn 14, Issue 9, 2008, Pages 2570-2578

  Licchesi, Julien D F ^a   Westra, William H ^b   Hooker, Craig M ^a   Herman, James G ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ATYPICAL ADENOMATOUS HYPERPLASIA; CONTROLLED STUDY; DAPK GENE; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; FEMALE; HTERT GENE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG ADENOMA; LUNG CARCINOGENESIS; MGMT GENE; PRIORITY JOURNAL; PROMOTER REGION; RARBETA GENE; RASSF1A GENE; TIMP3 GENE; TUMOR GENE; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; ADENOMA; GENETIC EPIGENESIS; GENETICS; HYPERPLASIA; LUNG; LUNG TUMOR; METABOLISM; PATHOLOGY; PRECANCER;

ADENOCARCINOMA; ADENOMA; DNA METHYLATION; EPIGENESIS, GENETIC; GENES, NEOPLASM; HUMANS; HYPERPLASIA; LUNG; LUNG NEOPLASMS; PRECANCEROUS CONDITIONS; PROMOTER REGIONS (GENETICS);

EID: 47949123984     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-2033     Document Type: Article

References (38)

1. American Cancer Society. Cancer tacts & figures 2007. Atlanta; 2007.
2. Hirsch FR, Franklin WA, Gazdar AF, Bunn PA, Jr. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res 2001;7:5-22.
3. Charloux A, Quoix E, Wolkove N, et al.The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 1997;26:14-23.
4. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003:123:21-49S.
5. Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005;40:90-7.
6. Westra WH. Early glandular neoplasia of the lung. Respir Res 2000;1:163-9.
7. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
8. Suzuki H.Watkins DN, Jair KW, et al. Epigenetic inac-tivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004;36:417-22.
9. Greenspan EJ, Jablonski MA, Rajan TV, et al. Epigenetic alterations in RASSF1A in human aberrant crypt foci. Carcinogenesis 2006;27:1316-22.
10. Esteller M, Sparks A, Toyota M, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 2000;60:4366-71.
11. Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci U S A 1999;96: 12754-9.
12. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998;95:11891-6.
13. Lamy A, Sesboue R, Bourguignon J, et al. Aberrant methylation of the CDKN2a/p16INK4a gene promoter region in preinvasive bronchial lesions: a prospective study in high-risk patients without invasive cancer. Int J Cancer 2002;100:189-93.
14. Machida EO, Brock MV, Hooker CM, et al. Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res 2006;66:6210-8.
15. Nakanishi K. Alveolar epithelial hyperplasia and adenocarcinoma of the lung. Arch Pathol Lab Med 1990; 114:363-8.
16. Kitamura H, Kameda Y, Nakamura N, et al. Proliferative potential and p53 overexpression in precursor and early stage lesions of bronchioloalveolar lung carcinoma. Am J Pathol 1995;146:876-87.
17. Kitamura H, Kameda Y, Nakamura N, et al. Atypical adenomatous hyperplasia and bronchoalveolar lung carcinoma. Analysis by morphometry and the expressions of p53 and carcinoembryonic antigen. Am J Surg Pathol 1996;20:553-62.
18. Herman JG, Graff JR. Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996:93:9821-6.
19. Otterson GA, Khleif SN, Chen W, Coxon AB, Kaye FJ. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine. Oncogene 1995;11:1211-6.
20. Bachman KE, Herman JG, Corn PG, et al. Methyla-tion-associated silencing of the tissue inhibitor of met-alloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999;59:798-802.
21. Toyooka S. Toyooka KO, Miyajima K, et al. Epigenetic down-regulation of death-associated protein kinase in lung cancers. Clin Cancer Res 2003;9:3034-41.
22. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-7.
23. Virmani AK, Rathi A, Zochbauer-Muller S, et al. Promoter methylation and silencing of the retinoic acid receptor- ß gene in lung carcinomas. J Natl Cancer Inst 2000;92:1303-7.
24. Agathanggelou A, Dallol A, Zochbauer-Muller S, et al. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers. Oncogene 2003;22:1580-8.
25. Zinn RL, Pruitt K, Eguchi S, Baylin SB, Herman JG. hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res 2007;67:194-201.
26. PalmisanoWA, Divine KK, Saccomanno G,et al.Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-8.
27. Zochbauer-Muller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001:61:249-55.
28. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001:93:691-9.
29. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004;4:707-17.
30. Slebos RJ, Baas IO, Clement MJ, et al, p53 alterations in atypical alveolar hyperplasia of the human lung. Hum Pathol 1998:29:801-8.
31. Wolf P, Hu YC, Doffek K, Sidransky D, Ahrendt SA. 0 (6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res 2001;61:8113-7.
32. Renaud S, Loukinov D, Abdullaev Z, et al. Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res 2007:35:1245-56.
33. Nakanishi K, Kawai T, Kumaki F, et al. Expression of human telomerase RNA component and telomerase reverse transcriptase mRNA in atypical adenomatous hyperplasia of the lung. Hum Pathol 2002;33:697-702.
34. Yim HW, Slebos RJ, Randell SH, et al. Smoking is associated with increased telomerase activity in short-term cultures of human bronchial epithelial cells. Cancer Lett 2007;246:24-33.
35. Pulling LC, Vuillemenot BR, Hutt JA, DevereuxTR, Belinsky SA. Aberrant promoter hypermethylation of the death-associated protein kinase gene is early and frequent in murine lung tumors induced by cigarette smoke and tobacco carcinogens. Cancer Res 2004;64:3844-8.
36. Vuillemenot BR, Pulling LC, PalmisanoWA, Hutt JA, Belinsky SA. Carcinogen exposure differentially modulates RAR-ß promoter hypermethylation, an early and frequent event in mouse lung carcinogenesis. Carcinogenesis 2004;25:623-9
37. Belinsky SA. Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 2005;26:1481-7.
38. Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006;66:3338-44.